Payment Cuts and the Future of Cardiac PET Access

A Medicare payment cut can look like a technical adjustment to a physician fee schedule, yet its effects can reach the waiting room. In the United States, the Centers for Medicare & Medicaid Services sets Medicare payment rates for many physician services. When those amounts fall faster than the cost of care, clinicians must absorb the difference or alter how they deliver services.

Cardiac PET—positron emission tomography used to assess heart muscle—is highly specialised. A study may involve FDG or perfusion tracer, advanced PET/CT equipment, a nuclear medicine technologist, a cardiologist or nuclear physician, and specialist reporting. Payment is only one part of access; staffing, tracer supply, equipment time and clinical demand determine whether a service remains viable.

Australian readers should not mistake a U.S. policy change for a cut to Australia’s Medicare benefits. Medicare Australia and the Medicare Benefits Schedule operate under different laws and budgets. The American College of Cardiology’s campaign concerns U.S. physician payments, but its lessons about diagnostic imaging, patient access and public advocacy are relevant to Australian debates.

The link between Medicare payment cuts and reduced access to cardiac PET scans is straightforward when margins become too thin, although no automatic causal chain exists. Services can be delayed, rationed or withdrawn. Patients may encounter longer waits, travel to another site or pay privately, while practices lose the volume needed to support specialised care.

How Fee Reductions Reach the Waiting Room

Medicare’s physician fee schedule converts payment weights into a dollar amount using an annual conversion factor. When Congress permits that amount to decline, a lower fee does not mean lower operating costs. Equipment servicing, radiopharmaceuticals, energy, insurance, administration and wages continue, placing disproportionate pressure on services with high fixed costs.

A reduction does not automatically remove Medicare coverage, and hospitals may also receive separate facility payments. Nevertheless, lower physician reimbursement can make it harder to justify staffing, evening clinics and equipment availability. Budgets may absorb the difference temporarily, concealing reduced capacity until a tracer delivery is missed, a technologist leaves or a major repair becomes unaffordable.

The effects can spread beyond patients who use Medicare. Commercial contracts may be renegotiated against lower reference rates, while employers and insurers monitor utilisation. If cardiologists lose confidence in a service, referrals may shift towards examinations that are easier to perform or reimburse, even when PET would provide the more clinically useful answer.

Why Cardiac PET Has a Narrow Margin

Cardiac imaging combines high fixed and variable costs. A PET/CT scanner is expensive to buy, maintain and certify; tracers must be ordered, delivered and administered under strict quality controls; and studies require secure interpretation. Hospitals cannot operate the equipment like an ordinary machine that can be switched off between bookings without creating a backlog.

Utilisation also affects clinical quality. Cardiac PET can help evaluate myocardial perfusion, viable heart muscle, inflammation and conditions such as cardiac sarcoidosis, depending on the indication and available tracer. Low volumes can make it difficult to maintain experienced teams, appropriate quality assurance and timely reporting for uncommon but important diagnoses.

Several revenue streams may support a cardiac PET service in the United States, including Medicare, commercial insurance and direct-pay arrangements. A fee reduction still matters because Medicare beneficiaries represent a substantial share of cardiology practices. Each patient contributes to the volume required to maintain a specialised unit, so reduced reimbursement can affect access for everyone using that facility.

Effects Patients Can Feel

A longer wait for cardiac imaging may delay management of suspected coronary disease, myocarditis or other cardiovascular conditions. It can also leave patients uncertain about whether their symptoms are safe to manage through exercise and medication. When a suitable scan is unavailable, clinicians may repeat less suitable tests or refer patients to distant centres.

Reduced capacity can create financial as well as clinical burdens. Patients may face travel, accommodation and time away from work, especially in rural communities. Private charges can arise where a service is not covered or a provider does not accept the available payment, adding stress for people already facing a serious diagnosis.

Personal accounts help advocacy campaigns show what administrative statistics can miss. A patient story can describe a cancelled appointment, a journey across state lines or a family’s decision to purchase a scan privately. Such accounts should be shared with consent and without identifying confidential details, allowing decision-makers to understand the practical consequences of payment policy.

Lessons for the Australian Health System

Australia’s Medicare Benefits Schedule lists eligible nuclear medicine and diagnostic imaging services, but listed pricing does not guarantee adequate local capacity. Public hospital patients are generally referred through specialist outpatient clinics or inpatient teams, while private patients commonly enter imaging through a general practitioner, specialist and imaging provider. Different pathways can produce different waiting times and out-of-pocket costs.

Access is also shaped by geography. Sydney and Melbourne have numerous hospital-based and private nuclear medicine services, including major PET centres. Patients in regional and remote areas may have fewer technologists, radiologists and cardiologists available, with travel sometimes required to capital cities. A payment adjustment that appears modest nationally can therefore have a much larger effect on a regional service with limited volume.

Australian providers also face costs associated with imported radiopharmaceuticals, equipment maintenance and replacement parts, making exchange rates and international supply chains relevant to service planning. Public hospital capital budgets and private health insurance arrangements influence how departments respond. Any local review should examine appointment availability, staffing, travel distances and out-of-pocket charges rather than relying only on published fees.

Responses That Can Reverse or Cushion Cuts

In the United States, CMS uses proposed and final rules to set payment methodology and can correct some implementation problems. Congress can change statutory rates or provide additional funds when scheduled reductions would otherwise take effect. Federal courts may review whether an agency followed administrative law, although litigation cannot by itself guarantee that a cardiac PET service remains financially sustainable.

The American College of Cardiology launched the Campaign for Patient Access to oppose payment reductions affecting cardiovascular care. Its approach combined policy analysis, news coverage, patient and clinician stories, submissions to federal agencies and calls for legislative action. This wider campaign model recognises that payment data is more persuasive when connected to documented effects on appointments, staffing and patients.

Australian advocacy operates through different channels, including Medicare consultations, parliamentary committees, state health departments, professional colleges and peak bodies. Stakeholders can contribute information about cardiac imaging capacity, delayed appointments and the financial sustainability of regional departments. Legal and legislative responses must be combined with practical measures because changing a published price alone will not create equipment, staff or available appointments.

Actions That Can Protect Scan Access

Several measures can help decision-makers move from identifying a payment problem to protecting essential imaging services.

• Commission a transparent review of cardiac PET costs, reimbursement and local access, including staffing, tracer expenses, equipment utilisation and waiting times.
• Tie public funding to service continuity through multi-year agreements that protect essential regional capacity while allowing transparent performance measures.
• Support reliable tracer delivery, equipment maintenance and workforce development so narrow-margin departments can maintain safe and timely services.
• Use coordinated referral pathways and specialist teleconsultation to support regional clinicians without duplicating services already available nearby.
• Build advocacy around verified data and consented patient stories, then present both to the agencies and lawmakers responsible for payment decisions.

Patients and families can contribute by documenting delays, travel and financial burdens and sharing their experiences with relevant campaigns, professional organisations or representatives. Clinicians can record cancelled studies, unfilled roles and referral patterns, while departments can provide anonymised capacity information. Evidence becomes more effective when it demonstrates where care is being delivered and where patients are being asked to wait.

Clinicians, patients and health organisations can also contact federal and state decision-makers, participate in Medicare consultations and ask how cardiac imaging access is being monitored. The campaign for patient access depends on a simple message: short-term budget adjustments can have lasting effects on specialised care. Add your voice, present the evidence and press for sustainable cardiac PET services before reduced capacity becomes embedded in the health system.